Semaglutide magani ne mai rage glucose wanda Novo Nordisk ya haɓaka don kula da nau'in ciwon sukari na 2. A cikin Yuni 2021, FDA ta amince da Semaglutide don tallata azaman maganin asarar nauyi (sunan ciniki Wegovy). Magungunan shine agonist mai karɓar glucagon-kamar peptide 1 (GLP-1) wanda zai iya kwaikwayi tasirinsa, rage yunwa, don haka rage cin abinci da adadin kuzari, don haka yana da tasiri a cikin asarar nauyi.
Baya ga amfani da shi don kula da nau'in ciwon sukari na 2 da kiba, an kuma gano Semaglutide don kare lafiyar zuciya da jijiyoyin jini, rage haɗarin cutar kansa, da kuma taimakawa barin sha. Bugu da ƙari, binciken biyu na baya-bayan nan ya nuna cewa Semaglutide zai iya rage haɗarin cututtukan koda da kuma cutar Alzheimer.
Nazarin da suka gabata sun nuna cewa asarar nauyi na iya sauƙaƙe alamun cututtukan osteoarthritis na gwiwa (ciki har da jin zafi). Koyaya, tasirin GLP-1 mai karɓar agonist mai asarar nauyi kamar Semaglutide akan sakamakon osteoarthritis na gwiwa a cikin mutane masu kiba ba a cika yin nazari ba.
A ranar 30 ga Oktoba, 2024, masu bincike daga Jami'ar Copenhagen da Novo Nordisk sun buga wata takarda bincike mai suna: Semaglutide sau ɗaya-mako-mako a cikin Mutanen da ke da Kiba da Knee Osteoarthritis a cikin New England Journal of Medicine (NEJM), babban mujallar likita ta duniya.
Wannan binciken na asibiti ya nuna cewa semaglutide na iya rage nauyi sosai kuma yana rage radadin da ke haifar da ciwon gwiwa da ke da alaƙa da kiba (sakamakon analgesic daidai yake da na opioids), da haɓaka ikon su na shiga cikin wasanni. Wannan kuma shine karo na farko da aka tabbatar da sabon nau'in magani na asarar nauyi, GLP-1 agonist mai karɓa don magance cututtukan arthritis.
Lokacin aikawa: Fabrairu-27-2025